Key facts
- It has raised $8.0M; the latest was Early Stage VC ($8.0M) in Nov 2025.
- Notable investors include Pillar VC, Age 1, KdT Ventures, Slocum Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Skeletalis
- ·The full record, as it builds
Funding rounds
No funding rounds for Skeletalis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Skeletalis
Developer of a targeted small-molecule delivery system designed for improving skeletal health. The company's platform concentrates therapeutic activity at sites of active bone loss while preserving natural bone remodeling, incorporates biomarker and imaging-friendly development pathways, and supports multiple indications through a single architecture, enabling healthcare providers to reduce fracture risk, maintain bone density, and advance treatment options for osteoporosis and related conditions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Website
- skeletalis.bio/
- Ownership
- Privately Held (backing)
Skeletalis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Skeletalis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Skeletalis in its N-PORT filings yet. We sweep new filings monthly.